Form 4: Tarsus Pharmaceuticals CFO Jeffrey Farrow Reports Stock Transactions
SEC Form 4 Filing
Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 15, 2025, Jeffrey Farrow, the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, engaged in transactions involving the company's stock.
- Farrow acquired 8,019 shares of common stock upon the settlement of vested Restricted Stock Units (RSUs).
- Farrow disposed of 8,019 shares of common stock.
- Following these transactions, Farrow directly owns 26,155 shares of common stock.
- Farrow also directly owns 24,060 Restricted Stock Units.
- The RSUs were granted on March 7, 2024, under the company's 2020 Stock Plan and vest in four equal installments on March 15th of each year from 2025 to 2028, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may provide shareholders with insight into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. |
| 03/15/2025 | Date of stock acquisition and disposal transactions. |
| 03/15/2025 | First vesting date for 25% of the RSUs. |
| 03/17/2025 | Date of derivative security transaction. |
| 03/18/2025 | Date of signature for the report. |
| 03/15/2026 | Second vesting date for 25% of the RSUs. |
| 03/15/2027 | Third vesting date for 25% of the RSUs. |
| 03/15/2028 | Final vesting date for 25% of the RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.